Summary
Philip Morris International Inc. (PM) has announced the sale of its subsidiary, Vectura Group Ltd., and its subsidiaries to Molex Asia Holdings Ltd. This strategic divestiture of its Vectura inhalation and respiratory drug delivery business is for an upfront cash consideration of approximately $198 million, with potential additional deferred payments of up to approximately $195 million contingent on future milestones extending to 2039. The transaction is anticipated to close by the end of 2024, pending regulatory approvals and other customary conditions. This sale is expected to result in an estimated loss of approximately $220 million for PM in the third quarter of 2024, before customary adjustments. While this divestiture may impact near-term earnings due to the recognized loss, it signals PM's continued focus on streamlining its portfolio and potentially reallocating capital towards its core reduced-risk products and growth initiatives.
Key Highlights
- 1PM to sell Vectura Group Ltd. and its subsidiaries to Molex Asia Holdings Ltd.
- 2Upfront cash consideration of GBP 150 million (approx. $198 million), subject to adjustments.
- 3Potential for up to GBP 148 million (approx. $195 million) in deferred payments based on future milestones through 2039.
- 4Transaction expected to close by the end of 2024, subject to regulatory and closing conditions.
- 5Estimated loss of approximately $220 million to be recorded in Q3 2024 related to the sale.
- 6Divestiture of the inhalation and respiratory drug delivery business.